These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 8408980)

  • 21. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
    Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
    [No Abstract]   [Full Text] [Related]  

  • 22. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
    van Vliet IM; den Boer JA; Westenberg HG
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):21-9. PubMed ID: 1638170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.
    Möller HJ; Volz HP
    J Affect Disord; 1992 Nov; 26(3):163-72. PubMed ID: 1460166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moclobemide versus tranylcypromine in the treatment of depression.
    Rossel L; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():61-2. PubMed ID: 2248075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
    Ketter TA; Post RM; Parekh PI; Worthington K
    J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases].
    Oostervink F; Bouvy PF; Touw DJ
    Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1937-40. PubMed ID: 14574773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective reversible monoamine oxidase-A inhibitor brofaromine and sleep.
    Hoffmans J; Knegtering R
    J Clin Psychopharmacol; 1993 Aug; 13(4):291-2. PubMed ID: 8376621
    [No Abstract]   [Full Text] [Related]  

  • 29. Combining tricyclic and monoamine oxidase inhibitor antidepressants.
    Spiker DG; Pugh DD
    Arch Gen Psychiatry; 1976 Jul; 33(7):828-30. PubMed ID: 942286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brofaromine in endogenous depression.
    Verhoeven WM
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):235-41. PubMed ID: 8208975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tranylcypromine isomers in depressed outpatients: effects on depression, monoamine oxidase inhibition and tyramine pressor response.
    Van de Merwe TJ; Pare CM; Glover V; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():189-202. PubMed ID: 6346066
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression.
    Thase ME; Mallinger AG; McKnight D; Himmelhoch JM
    Am J Psychiatry; 1992 Feb; 149(2):195-8. PubMed ID: 1734739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor--an open study.
    Delcker A; Gaertner HJ
    Eur Neuropsychopharmacol; 1991 May; 1(2):177-80. PubMed ID: 1821707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
    Fahlén T; Nilsson HL; Borg K; Humble M; Pauli U
    Acta Psychiatr Scand; 1995 Nov; 92(5):351-8. PubMed ID: 8619339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression.
    Steiger A; Holsboer F; Gerken A; Demisch L; Benkert O
    Pharmacopsychiatry; 1987 Nov; 20(6):262-9. PubMed ID: 3432361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tranylcypromine in narcolepsy.
    Gernaat HB; Haffmans PM; Knegtering H; Birkenhäger TK
    Pharmacopsychiatry; 1995 May; 28(3):98-100. PubMed ID: 7568373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of lithium-tranylcypromine treatment in refractory depression.
    Price LH; Charney DS; Heninger GR
    Am J Psychiatry; 1985 May; 142(5):619-23. PubMed ID: 3920923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined therapy with tricyclic and MAOI antidepressants in the treatment of resistant major depression].
    Rosan TA; Mesones HL; Brengio F
    Acta Psiquiatr Psicol Am Lat; 1994 Dec; 40(4):314-20. PubMed ID: 7484185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.